Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765674 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,191
- Enrollment target
NCT00765674: Completed Phase 3 study, sponsored by Novartis.
NCT00765674 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 1,191 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00765674, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,191 participants
- Enrollment target
Study Summary
This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.
Primary Outcome
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \< 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate si
Interventions
- DRUG Placebo
- DRUG Amlodipine
- DRUG Aliskiren
- DRUG Hydrochlorothiazide (HCTZ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,191 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
What the finished NCT00765674 record still lists
NCT00765674 is an interventional study that assigns participants to a tested intervention. Its 1,191 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00765674 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00765674 about?
NCT00765674 is a clinical study titled "Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension". This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.
What is the current status of trial NCT00765674?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,191 participants. The study started on 2008-09. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00765674?
The interventions under investigation include: Placebo (DRUG), Amlodipine (DRUG), Aliskiren (DRUG), Hydrochlorothiazide (HCTZ) (DRUG).
Who is sponsoring clinical trial NCT00765674?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00765674's enrollment target sits among peer trials
1,191 229th of 2000 higher than 1,772 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05580419 · 1,188 participants · NA
Impact of 4PCP on Practitioner and Patient Outcomes
- NCT06290869 · 1,188 participants · Phase 3
Tobacco Education and Lung Health Study (TEAL)
- NCT07177339 · 1,196 participants · Phase 3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia